Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,269,000
Closed -$36.7M 3272
2024
Q3
$36.7M Sell
1,269,000
-399,600
-24% -$11.7M 0.08% 141
2024
Q2
$46.7M Sell
1,668,600
-786,100
-32% -$21.6M 0.1% 109
2024
Q1
$68.1M Sell
2,454,700
-590,400
-19% -$16.4M 0.13% 73
2023
Q4
$87.7M Buy
3,045,100
+1,381,800
+83% +$41.8M 0.15% 60
2023
Q3
$55.2M Buy
+1,663,300
New +$58.8M 0.1% 102

Other funds holding PFE

GTS Securities's PFE Position: Q2 2026 in Review

GTS Securities reduced its Pfizer (PFE) stake by 2.8% in Q2 2026, selling an estimated $10.5K and leaving 14,176 shares worth $341K. The position accounts for 0.01% of the portfolio, ranked #912.

GTS Securities first reported a position in PFE in Q2 2023 and has held it in 12 quarters since. The position peaked at $41.8M in Q4 2023. 2,835 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • GTS Securities held 14,176 shares of Pfizer worth $341K as of Q2 2026.
  • GTS Securities sold 403 Pfizer shares in Q2 2026, an estimated $10.5K.
  • Pfizer made up 0.01% of GTS Securities's portfolio in Q2 2026, its #912 holding.
  • GTS Securities first reported a position in Pfizer in Q2 2023 and has held it in 12 quarters since.
  • GTS Securities's Pfizer position peaked at $41.8M in Q4 2023.
  • 2,835 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.